WallStSmart

Compania de Minas Buenaventura SAA ADR (BVN)vsVersamet Royalties Corporation Common Stock (VMET)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Compania de Minas Buenaventura SAA ADR generates 3606% more annual revenue ($2.05B vs $55.27M). VMET leads profitability with a 58.4% profit margin vs 47.7%. BVN trades at a lower P/E of 7.9x. BVN earns a higher WallStSmart Score of 84/100 (A-).

BVN

Exceptional Buy

84

out of 100

Grade: A-

Growth: 10.0Profit: 9.0Value: 8.0Quality: 8.0
Piotroski: 5/9Altman Z: 3.10

VMET

Buy

58

out of 100

Grade: C

Growth: 10.0Profit: 8.5Value: 4.7Quality: 7.5
Piotroski: 5/9Altman Z: 1.19
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BVNUndervalued (+16.1%)

Margin of Safety

+16.1%

Fair Value

$48.26

Current Price

$29.72

$18.54 discount

UndervaluedFair: $48.26Overvalued

Intrinsic value data unavailable for VMET.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BVN6 strengths · Avg: 10.0/10
P/E RatioValuation
7.9x10/10

Attractively priced relative to earnings

Profit MarginProfitability
47.7%10/10

Keeps 48 of every $100 in revenue as profit

Operating MarginProfitability
52.5%10/10

Strong operational efficiency at 52.5%

Revenue GrowthGrowth
103.0%10/10

Revenue surging 103.0% year-over-year

EPS GrowthGrowth
139.4%10/10

Earnings expanding 139.4% YoY

Altman Z-ScoreHealth
3.1010/10

Safe zone — low bankruptcy risk

VMET5 strengths · Avg: 9.8/10
Profit MarginProfitability
58.4%10/10

Keeps 58 of every $100 in revenue as profit

Operating MarginProfitability
90.6%10/10

Strong operational efficiency at 90.6%

Revenue GrowthGrowth
594.0%10/10

Revenue surging 594.0% year-over-year

EPS GrowthGrowth
573.0%10/10

Earnings expanding 573.0% YoY

Debt/EquityHealth
0.129/10

Conservative balance sheet, low leverage

Areas to Watch

BVN0 concerns · Avg: 0/10

No major concerns identified

VMET3 concerns · Avg: 3.0/10
P/E RatioValuation
37.5x4/10

Premium valuation, high expectations priced in

Market CapQuality
$1.26B3/10

Smaller company, higher risk/reward

Altman Z-ScoreHealth
1.192/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : BVN

The strongest argument for BVN centers on P/E Ratio, Profit Margin, Operating Margin. Profitability is solid with margins at 47.7% and operating margin at 52.5%. Revenue growth of 103.0% demonstrates continued momentum.

Bull Case : VMET

The strongest argument for VMET centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 58.4% and operating margin at 90.6%. Revenue growth of 594.0% demonstrates continued momentum.

Bear Case : BVN

No major red flags identified for BVN, but monitor valuation.

Bear Case : VMET

The primary concerns for VMET are P/E Ratio, Market Cap, Altman Z-Score.

Key Dynamics to Monitor

VMET is growing revenue faster at 594.0% — sustainability is the question.

BVN generates stronger free cash flow (232M), providing more financial flexibility.

Monitor OTHER PRECIOUS METALS & MINING industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BVN scores higher overall (84/100 vs 58/100), backed by strong 47.7% margins and 103.0% revenue growth. Both earn "Exceptional Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Compania de Minas Buenaventura SAA ADR

BASIC MATERIALS · OTHER PRECIOUS METALS & MINING · USA

Compaa de Minas Buenaventura SAA, a precious metals company, is dedicated to the exploration, extraction, concentration, smelting and commercialization of minerals and polymetallic metals in Peru, the United States, Europe and Asia. The company is headquartered in Lima, Peru.

Visit Website →

Versamet Royalties Corporation Common Stock

BASIC MATERIALS · OTHER PRECIOUS METALS & MINING · USA

Viamet Pharmaceuticals Corp (VMET) is a biopharmaceutical company focused on developing cutting-edge therapeutics for serious diseases, leveraging its proprietary metalloenzyme-based technology platform. The company is committed to addressing significant unmet medical needs in fungal infections and oncology, positioning itself as a leader in therapeutic innovation. With a diverse pipeline bolstered by strategic collaborations and a strong intellectual property portfolio, Viamet is well-prepared to advance its clinical initiatives and enhance shareholder value, aiming to redefine treatment approaches in its specialized therapeutic areas.

Want to dig deeper into these stocks?